Since 2009, several clinical trial results reported findings that will likely change the way patients with acute myeloid leukemia (AML), multiple myeloma, breast cancer as well as children with high-risk neuroblastoma are treated. In addition, the discovery of certain gene alterations in children with acute lymphoblastic leukemia (ALL) has uncovered potential new targets for therapeutic approaches in this disease.
- Improving Outcome for Children with High-Risk Neuroblastoma
- High Dose Chemotherapy Significantly Prolongs Survival for Patients with Acute Myeloid Leukemia
- Lenalidomide for Multiple Myeloma Demonstrated to Significantly Extend Progression-Free Survival
- Disease-Free Breast Cancer Survival Improves When Herceptin is Used With Chemotherapy
- Childhood Cancer TARGET Initiative Acute Lymphoblastic Leukemia Discoveries
Jeffrey S. Abrams, M.D., has led the Cancer Therapy Evaluation Program (CTEP) since June 2007. Dr. Abrams came to CTEP in 1993 when he joined as a clinical research scientist to oversee the breast cancer treatment trials portfolio and participate in clinical trials at the NIH Clinical Center and the National Naval Medical Center. More…